PALVELLA THERAPEUTICS, INC. 8-K

What Happened
Palvella Therapeutics, Inc. (PVLA) announced an underwriting agreement dated February 25, 2026 and filed an 8‑K reporting a registered public offering of 1,600,000 shares of common stock at $125.00 per share. The offering is being led by TD Securities (USA) LLC, Cantor Fitzgerald & Co. and Stifel, Nicolaus & Company, Incorporated as representatives of the underwriters. The company filed a prospectus supplement on February 25 (filed with the SEC February 26) and expects the offering to close on or about February 27, 2026, subject to customary closing conditions.

Key Details

• Offering size: 1,600,000 Firm Shares at $125.00/share (gross proceeds ≈ $200.0M).
• Net proceeds: estimated at approximately $187.3 million after underwriting discounts, commissions and estimated offering expenses.
• Additional option: underwriters have a 30‑day option to purchase up to 240,000 additional shares at the public offering price.
• Use of proceeds: to support development of QTORIN rapamycin and QTORIN pitavastatin programs, plus working capital and general corporate purposes.

Why It Matters
This is a primary equity raise by Palvella to provide cash for its drug development programs and operations. The estimated $187.3M in net proceeds should bolster funding for the QTORIN programs and near‑term R&D. Because all shares are being issued by the company, the transaction will increase the company’s outstanding share count if completed (and more so if the underwriters’ option is exercised), which is a key consideration for current shareholders.